Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension

• Published in: Journal of the American College of Cardiology Vol. 78; no. 14; pp. 1393 - 1403
• Main Authors: Chin, Kelly M., Sitbon, Olivier, Doelberg, Martin, Feldman, Jeremy, Gibbs, J. Simon R., Grünig, Ekkehard, Hoeper, Marius M., Martin, Nicolas, Mathai, Stephen C., McLaughlin, Vallerie V., Perchenet, Loïc, Poch, David, Saggar, Rajan, Simonneau, Gérald, Galiè, Nazzareno
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 05.10.2021; Elsevier
• Subjects: Acetamides - therapeutic use; Adult; Aged; Antihypertensive Agents - therapeutic use; Cardiovascular; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists - therapeutic use; Female; Humans; Life Sciences; macitentan; Male; Middle Aged; Phosphodiesterase 5 Inhibitors - therapeutic use; pulmonary arterial hypertension; Pulmonary Arterial Hypertension - drug therapy; Pyrazines - therapeutic use; Pyrimidines - therapeutic use; randomized controlled trial; selexipag; Sulfonamides - therapeutic use; Tadalafil - therapeutic use; triple combination therapy; selexipag; PDE5i; triple combination therapy; AE; CI; PVR; randomized controlled trial; NT-proBNP; macitentan; ERA; PAH; pulmonary arterial hypertension; 6MWD; FC; functional class; adverse event; 6-minute walk distance; phosphodiesterase type-5 inhibitor; N-terminal pro–brain natriuretic peptide; endothelin receptor antagonist; confidence interval; pulmonary vascular resistance

In pulmonary arterial hypertension (PAH), there are no data comparing initial triple oral therapy with initial double oral therapy. TRITON (The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension; NCT0255...